New hope drug enters first human tests for tough cancers
NCT ID NCT07348211
Summary
This is the first study in people to test a new cancer drug called SIM0610. It aims to find a safe dose and see if it can shrink tumors in adults with advanced solid cancers that have stopped responding to standard treatments. The study will enroll 260 people with cancers like lung, colorectal, head and neck, and liver cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing Cancer Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400000, China
Contact
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150000, China
Contact
-
Shanghai East Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact
-
The Affiliated Cancer Hospital of Shandong First Medical University& Shan Dong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact
-
Zhongshan Hospital, Fudan University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact
-
the First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
Contact
Conditions
Explore the condition pages connected to this study.